Related Experiment Video
Updated: Sep 14, 2026
Candida albicans Biofilm Chip (CaBChip) for High-throughput Antifungal Drug Screening
Published on: July 18, 2012
Evaluation of differential gene expression in fluconazole-susceptible and -resistant isolates of Candida albicans by
P David Rogers1, Katherine S Barker
1Departments of Clinical Pharmacy. Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, USA. drogers@utmem.edu
Abstract:
The opportunistic fungal pathogen Candida albicans is the major causative agent of oropharyngeal candidiasis (OPC) in AIDS. The development of azoles, such as fluconazole, for the treatment of OPC has proven effective except in cases where C. albicans develops resistance to fluconazole during the course of treatment. In the present study, we used microarray technology to examine differences in gene expression from a fluconazole-susceptible and a fluconazole-resistant well-characterized, clinically obtained matched set of C. albicans isolates to identify genes which are differentially expressed in association with azole resistance. Among genes found to be differentially expressed were those involved in amino acid and carbohydrate metabolism; cell stress, cell wall maintenance; lipid, fatty acid, and sterol metabolism; and small molecule transport. In addition to CDR1, which has previously been demonstrated to be associated with azole resistance, the drug resistance gene RTA3, the ergosterol biosynthesis gene ERG2, and the cell stress genes CRD2, GPX1, and IFD5 were found to be upregulated. Several genes, such as the mitochondrial aldehyde dehydrogenase gene ALD5, the glycosylphosphatidylinositol synthesis gene GPI1, and the iron transport genes FET34 and FTR2 were found to be downregulated. Further study of these differentially regulated genes is warranted to evaluate how they may be involved in azole resistance. In addition to these novel findings, we demonstrate the utility of microarray analysis for studying the molecular mechanisms of drug resistance in pathogenic organisms.
Insights
This study identifies genes involved in Candida albicans resistance to fluconazole, an antifungal drug used to treat oropharyngeal candidiasis in AIDS patients. Microarray analysis revealed differentially expressed genes related to metabolism, cell stress, and drug transport.
Area of Science:
- Medical Mycology
- Molecular Biology
- Antimicrobial Resistance
Background:
- Candida albicans is a fungal pathogen causing oropharyngeal candidiasis (OPC), particularly in AIDS patients.
- Azole antifungals like fluconazole are effective treatments for OPC, but resistance can develop.
- Understanding the genetic basis of fluconazole resistance is crucial for effective treatment strategies.
Purpose of the Study:
- To identify genes differentially expressed in fluconazole-resistant Candida albicans compared to susceptible strains.
- To elucidate the molecular mechanisms underlying azole resistance in this opportunistic pathogen.
Main Methods:
- Utilized microarray technology to compare gene expression profiles of matched fluconazole-susceptible and -resistant Candida albicans clinical isolates.
- Analyzed differential gene expression patterns associated with azole resistance.
Main Results:
- Identified differentially expressed genes involved in amino acid and carbohydrate metabolism, cell stress, cell wall maintenance, lipid metabolism, and small molecule transport.
- Confirmed upregulation of CDR1, RTA3 (drug resistance), ERG2 (ergosterol biosynthesis), CRD2, GPX1, and IFD5 (cell stress) genes.
- Observed downregulation of ALD5 (aldehyde dehydrogenase), GPI1 (GPI synthesis), FET34, and FTR2 (iron transport) genes.
Conclusions:
- Microarray analysis is a valuable tool for investigating molecular mechanisms of drug resistance in pathogenic fungi.
- Several novel genes and pathways are implicated in Candida albicans fluconazole resistance, warranting further investigation.
- Findings contribute to a deeper understanding of antifungal resistance, potentially guiding future therapeutic approaches.
